Request Trial
shutterstock_1730094274_metamorworks
metamorworks / Shutterstock.com
24 June 2021PharmaMuireann Bolger

SPCs outlive patent protections in 91% of cases, new report reveals

Supplementary protection certificates (SPCs) outlive medicinal patents in more than nine in ten cases, a new report has found.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Beyond the primary patent: How pharma can build competitive barriers
16 September 2026   A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.
Pharma
J&J unit win shuts door on Sandoz generic launch
10 September 2026   Four patents stood firm in a Johnson & Johnson unit’s fight with Sandoz, leaving the generics maker facing a lengthy wait before its esketamine nasal spray can reach the US market.
Pharma
Italy’s Biofer falls short in Fed Circ appeal over key claim wording
7 September 2026   A single phrase in a patent has proved decisive in Biofer’s infringement fight with Vifor, with the Federal Circuit exposing the risks of small claim-drafting choices for life sciences companies.


Editor's picks

Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients
Regulation & Industry
Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients
14 September 2026

Editor's picks

Regulation & Industry
Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients
14 September 2026
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026
Regulation & Industry
Why is 2026 already a record year for M&A activity?
17 July 2026

More features

Amgen hit with lawsuit over its proposed Opdivo biosimilar
Beyond the primary patent: How pharma can build competitive barriers
Australian biotech sues Grail over multi-cancer blood test
K&L Gates hires six-partner team of IP and corporate lawyers from Pillsbury
Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients
Built to be bought? What makes companies acquisition-ready
Patent lawyers and judges discuss lofty UPC issues in grand London venue
J&J names two-decade veteran as chief IP counsel